



Certificate of Mailing:

The undersigned certifies that this correspondence is being sent via first-class mail, postage prepaid, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, this 24th day of June, 2004.

(s)

Linda S. Evans

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Darrow et al.	Atty. Docket:	ORT-1566
Serial No.:	10/040,655	Art Unit:	1652
Filed:	January 7, 2002	Examiner:	William W. Moore
For:	DNA Encoding the Human Serine Protease T		

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

This Statement is supplemental to the Information Disclosure Statements filed with the above-identified application on July 16, 2003, and January 7, 2002. Pursuant to 37 C.F.R. § 1.56 and in accordance with 37 C.F.R. §§ 1.97-1.98, Applicant submits the accompanying Form PTO-1449 citing references relating to the application.

This Statement is being filed under the provisions of 37 C.F.R. § 1.97(d). Please charge the \$180.00 fee set forth at 37 C.F.R. § 1.17(p), and any other required fees due in connection with the filing of this paper, to Deposit Account No. 10-0750 (a duplicate of this paper is enclosed). The statement as specified at 37 C.F.R. § 1.97(e) is provided below.

Each reference listed on the enclosed form was first cited in a counterpart European application in a Communication of a Supplementary Partial European Search

Report not more than three months prior to the filing of this Statement. A copy of the Communication, which is dated May 12, 2004, is enclosed.

A copy of each of the references listed on the enclosed Form PTO-1449 is enclosed. Each reference is in the English language.


This Statement should not be construed as an admission that any information provided herewith is material as that term is defined in 37 C.F.R. § 1.56(b) or that each of the cited references qualifies as prior art. This Statement should not be construed as a representation that a search has been made, or that information more material does not exist.

The Examiner is respectfully requested to initial the citations on the Form PTO-1449 to confirm consideration of each reference.

If any fees are due in connection with the filing of this Statement, please charge any necessary

Respectfully submitted,

Date: June 24, 2004

  
Linda S. Evans  
Reg. No. 33,873

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, New Jersey 08933-7003  
(858) 320-3406



FORM PTO-144

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

SERIAL NO.

ORT-1566

10/040,655

**INFORMATION DISCLOSURE  
CITATION BY APPLICANT**

(Use several sheets if necessary)

APPLICANT  
Darrow et al.FILING DATE  
January 7, 2002GROUP ART UNIT  
1652**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	INVENTORS	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY/REGION	CLASS	SUBCLASS	TRANSLATION (if applicable)
	WO	0 1 3 5 4 4 0	17 May 2001	WIPO			

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

		Database EMBL EBI accession no. HSZZ26836, 18 April 1997, Adams et al., "Initial Assessment Of Human Gene Diversity And Expression Patterns Based Upon 83 Million Basepairs Of cDNA Sequence".
		Database EMBL accession no. AI272325, 23 November 1998, Hillier et al., "WashU-NCI Human EST Project".

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.